Yuval MSc - Bio View Ex VP
| BIOV Stock | ILS 26.70 0.50 1.91% |
Insider
Yuval MSc is Ex VP of Bio View
| Age | 62 |
| Phone | 972 73 227 1025 |
| Web | https://www.bioview.com |
Bio View Management Efficiency
Bio View's management efficiency ratios could be used to measure how well Bio View manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Advocate IrShai | Menora Miv Hld | 64 | |
| Hagai Schreiber | The Phoenix Holdings | 48 | |
| Yitzhak Oz | The Phoenix Holdings | 58 | |
| Asaf Shaham | Migdal Insurance | 54 | |
| Moni Feller | The Phoenix Holdings | N/A | |
| Sami Babecov | Harel Insurance Investments | 60 | |
| Ronen Kantor | XTL Biopharmaceuticals | N/A | |
| Aryhe CPA | Harel Insurance Investments | 49 | |
| Hadar BreenWeiss | Clal Insurance Enterprises | 53 | |
| Menachem Neeman | The Phoenix Holdings | 53 | |
| Eli Schwartz | The Phoenix Holdings | 48 | |
| Uri Aldubi | Israel Opportunity | 58 | |
| Shlomo Shalev | XTL Biopharmaceuticals | 61 | |
| Uri Schor | Harel Insurance Investments | N/A | |
| Nataly MishanZakai | Harel Insurance Investments | 49 | |
| Rony Halman | Israel Opportunity | 58 | |
| Amir Shelah | Migdal Insurance | 65 | |
| Israel Feldinger | Israel Opportunity | 35 | |
| Eran Cherninsky | Clal Insurance Enterprises | 61 | |
| Dan BarOn | Menora Miv Hld | 59 | |
| Sammy Bassat | Harel Insurance Investments | 76 | |
Management Performance
| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 |
Bio View Leadership Team
Elected by the shareholders, the Bio View's board of directors comprises two types of representatives: Bio View inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio View's management team and ensure that shareholders' interests are well served. Bio View's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio View's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan Schwebel, CEO and Pres | ||
| Elad Kfir, Vice President of Marketing | ||
| Yulia CPA, Chief Officer | ||
| Inbal Hillel, Vice President - Operations | ||
| Yuval MSc, Ex VP | ||
| David Kutas, CEO of BioView Inc - USA and President of BioView Inc - USA |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio View a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 35.4 M | |||
| Shares Outstanding | 13.75 M | |||
| Shares Owned By Insiders | 51.58 % | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 1.71 X | |||
| Revenue | 30.51 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Bio Stock
Bio View financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio View security.